|
Real-time Estimate
Cboe BZX
16:56:53 17/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 135.86 USD | -0.84% |
|
-4.02% | -25.91% |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 7,207 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | -21.73% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 7,054 | 6,781 | 6,389 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | -22.25% | -3.87% | -5.79% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -53.9x | 39.7x | 13.4x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 75.4x | 33.2x | 12.3x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 1.7x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 7.55x | 4.93x | 3.49x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 7.39x | 4.64x | 3.09x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -59.2x | 51.7x | 17.9x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -55.9x | 33x | 9.75x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -37.6x | 19.3x | 9.1x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -2.66% | 5.18% | 11% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -2.54 | 3.453 | 10.23 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 954.3 | 1,461 | 2,066 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -119.1 | 131.2 | 356.3 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -126.2 | 205.7 | 655.1 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -132.1 | 191.6 | 580.3 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -152.9 | -425.6 | -818 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 137.01 | 137.01 | 137.01 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 52,600 | - | - |
| Announcement Date | 01/03/22 | 27/02/23 | 20/02/24 | 18/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -53.94x | 7.39x | -59.22x | -.--% | 7.21B | ||
| 41.9x | 14.18x | 30.07x | 0.48% | 1,275B | ||
| 41.35x | 6.94x | 19.51x | 1.89% | 680B | ||
| 37.55x | 8.61x | 17.78x | 2.34% | 521B | ||
| 22x | 5.33x | 13.34x | 2.45% | 389B | ||
| 102.54x | 5.86x | 24.97x | 2.35% | 356B | ||
| 24.41x | 5.87x | 14.28x | 2.7% | 305B | ||
| 24.28x | 4.86x | 13.64x | 1.8% | 287B | ||
| 23.87x | 7.33x | 13.47x | 2.18% | 250B | ||
| -39.41x | 7.29x | 45.94x | 1.97% | 208B | ||
| Average | 22.45x | 7.37x | 13.38x | 1.82% | 428B | |
| Weighted average by Cap. | 36.93x | 8.89x | 22.37x | 1.68% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















